Search

A study conducted by researchers at Nanjing Medical University in Lianyungang, People's Republic of China, focused on the comparative efficacy of different concentrations of chlorhexidine in preventing ventilator-associated pneumonia in intensive care units. The study included 19 trials with 3183 participants across nine countries and found that the use of 2.0% chlorhexidine and 0.12% chlorhexidine reduced the risk of ventilator-associated pneumonia compared to a placebo. The research concluded that 2.0% chlorhexidine was superior to other concentrations in preventing ventilator-associated pneumonia in critically ill patients. [Extracted from the article]

Researchers from Indiana University School of Medicine conducted a study on early-onset ventilator-associated pneumonia (VAP) in pediatric severe traumatic brain injury (TBI) patients. The study aimed to describe VAP, its microbiology, and differences in frequency based on various definitions. Findings showed that VAP occurred in 27-41% of patients, with methicillin-sensitive Staphylococcus aureus being the most common isolate. Nebulized 3% saline and albuterol were associated with a reduced incidence of VAP, highlighting the need for further investigation into potential interventions. [Extracted from the article]

Researchers at Hospital Universitario Son Espases in Palma de Mallorca, Spain, have developed a hybridization-based capture system to monitor antimicrobial resistance in Pseudomonas aeruginosa directly from clinical samples. The system was tested in vitro and in vivo, showing promising results in identifying resistance mutations and monitoring population dynamics. This study highlights the potential for rapid and cost-effective diagnostics of bacterial infections, offering insights into the evolution of resistance in P. aeruginosa. [Extracted from the article]

A recent study conducted at the University of Kansas examined the impact of antibiotic initiation timing on in-hospital mortality in trauma patients with Ventilator-Associated Pneumonia (VAP). The research found that survivors had antibiotics initiated in a more delayed fashion compared to non-survivors. These findings suggest that early antibiotic administration for suspected infection may not be necessary in all cases. The study was published in The American Surgeon and has been peer-reviewed. [Extracted from the article]

The article discusses the role of Clinical Pulmonary Infection Score and Sonopulmonary Infection Score in diagnosing and predicting outcomes of Ventilator-Associated Pneumonia (VAP) in Respiratory Intensive Care Units (RICU). It explains the classification scheme for pneumonia in UK NHS hospitals based on the setting of infection acquisition and the different causative pathogens and treatment strategies for community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and VAP. The clinical trial NCT06640374, conducted by Assiut University, aims to study the diagnosis and outcomes of VAP in RICU patients using these scores. [Extracted from the article]

A recent study conducted at the University of Florida focused on defining pathogen and susceptibility patterns for early versus late ventilator-associated pneumonia (VAP) in trauma patients to guide empiric treatment decisions. The research found that trauma patients with early-VAP have a decreased risk of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa infections. The study highlighted the importance of individual institutions conducting similar analyses to ensure appropriate initial treatment of VAP. [Extracted from the article]

Researchers from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences have published findings on ventilator-associated pneumonia in critical care pharmacotherapy literature for 2023. The study aimed to summarize impactful publications on pharmacotherapeutic care for critically ill patients, including topics such as hydrocortisone for severe community-acquired pneumonia and inhaled amikacin for preventing ventilator-associated pneumonia. The review provides insights into advances in pharmacotherapeutic care for critically ill patients, offering a perspective on the potential impact of the most relevant articles from 2023. [Extracted from the article]

A patent has been issued to Nevap Inc. for systems and devices that prevent occlusion of a suction line in a medical device. The invention aims to address the inefficiency of prior art suctioning means in preventing secretions and pathogens from traveling through tracheal tubes and into the patient's lungs, potentially causing diseases such as ventilator-associated pneumonia. The system includes a flexible tube with an inflatable balloon, a suction line, and a spacer to prevent occlusion of the suction line port. The patent provides detailed descriptions and claims for the invention. [Extracted from the article]

A recent study conducted at National Yang Ming Chiao Tung University in Taiwan compared the clinical outcomes of ventilator-associated pneumonia (VAP) patients with and without chronic obstructive pulmonary disease (COPD). The study found that COPD was not associated with worse clinical outcomes in VAP patients, and there were no significant differences in bacterial etiology between the two groups. The research provides valuable insights into the relationship between COPD and VAP, highlighting the need for further investigation in this area. [Extracted from the article]

A report from the B.P. Koirala Institute of Health Sciences discusses the research findings on ventilator-associated pneumonia caused by Acinetobacter baumannii. The report focuses on the approval and implications of sulbactam-durlobactam therapy (SUL-DUR) in treating hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). SUL-DUR, marketed as Xacduro, is a combination of sulbactam and durlobactam that acts as a narrow-spectrum antibiotic. Clinical trials have shown that SUL-DUR is safe and effective in treating A. baumannii-related VAP, HAP, and bacteremia. The report concludes that SUL-DUR shows promise as a treatment option for HAP and VAP caused by the Acinetobacter baumannii-calcoaceticus complex. [Extracted from the article]

Researchers from the Federal University of Minas Gerais in Brazil have developed a new diagnostic method called droplet digital PCR (ddPCR) to detect and quantify Acinetobacter baumannii in bronchoalveolar lavage samples from patients with ventilator-associated pneumonia (VAP). VAP is a severe healthcare infection that affects the lungs and carries a high risk of morbidity and mortality. The study found that ddPCR was more sensitive than other molecular techniques and detected/quantified A. baumannii in more clinical samples. This emerging technology offers promising advantages for the timely and effective management of VAP. [Extracted from the article]

A recent study conducted by researchers at the University of Antwerp in Belgium has explored a novel approach to prevent ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections. The researchers developed an antibacterial hydrogel coating using the polymyxin B (PMB) peptide to prevent bacterial adhesion to the polymeric substrate. The coating demonstrated antibacterial and anti-biofilm effects against Pseudomonas aeruginosa, a pathogen associated with high morbidity and mortality rates in mechanically ventilated patients. The study suggests that this peptide-releasing hydrogel formula could serve as a foundation for preventing VAP. [Extracted from the article]

A recent case report from the First Hospital of Jilin University highlights a new-found opportunistic fungal pathogen called Myceliophthora heterothallica, which caused ventilator-associated pneumonia in an elderly patient. This fungus, previously considered environmental and non-pathogenic, was cultured from the patient's endotracheal aspirates. The patient was successfully treated with piperacillin-tazobactam and recovered from the infection. This case report provides valuable insights into the clinical diagnosis and treatment of Myceliophthora heterothallica infection and expands our knowledge of new pathogenic species. [Extracted from the article]

A recent report from the University of Iowa discusses the implementation of a respiratory therapist-driven mechanical ventilation protocol in adult ICUs. The protocol aimed to increase adherence to lung-protective ventilation guidelines and decrease pulmonary complications. The study included 666 subjects and found that the post-intervention group had a significant increase in adherence to guidelines and a lower incidence of acute respiratory distress syndrome (ARDS). However, there was no difference in other clinical outcomes such as ventilator-associated pneumonia or ICU mortality. The research suggests that the protocol was associated with increased lung protective ventilation and decreased ARDS incidence. [Extracted from the article]

A study conducted at Hebei Chest Hospital in China evaluated the effectiveness of comprehensive airway management intervention on ventilator-associated pneumonia (VAP) in ICU patients requiring mechanical ventilation. The study compared a control group receiving routine nursing intervention to an observation group receiving comprehensive airway management intervention. The observation group showed significant improvements in clinical symptoms, shorter duration of mechanical ventilation and hospitalization, and higher nursing satisfaction and quality scores. The study concluded that comprehensive airway management can reduce the occurrence of VAP in ICU patients. [Extracted from the article]

A new study conducted by researchers at Hamad Medical Corporation in Doha, Qatar, explores the use of noble element coatings on endotracheal tubes (ETTs) to prevent ventilator-associated pneumonia (VAP). The study found that noble metal-coated ETTs were effective in reducing the incidence of VAP compared to noncoated ETTs. However, there was no significant impact on mortality rates, duration of mechanical ventilation, or length of stay in the intensive care unit (ICU). The researchers recommend integrating these coated ETTs into a comprehensive care plan for emergency care settings. [Extracted from the article]

A recent study conducted at New York University (NYU) Langone Health aimed to improve the accuracy and automation of existing algorithms used to diagnose ventilator-associated pneumonia (VAP). The researchers created a semi-automated VAP surveillance system based on the Centers for Disease Control & Prevention (CDC) definition of ventilator-associated events (VAE). After retrospective assessment, the system correctly identified 61% of potential VAP cases, with a VAP rate of 1.5 infections per 1000 ventilation days. The study highlights the need for improved surveillance systems and earlier interventions to reduce the risk of VAP and improve patient outcomes. [Extracted from the article]

A recent study conducted by the All India Institute of Medical Sciences (AIIMS) focused on ventilator-associated pneumonia (VAP). VAP is defined as pneumonia that occurs more than 48 hours after endotracheal intubation, during mechanical ventilation, or after extubation. The study aimed to identify the pathogens commonly associated with VAP and determine their antibiotic susceptibility patterns. The researchers emphasized the importance of early and accurate diagnosis of VAP to optimize antibiotic therapy and reduce complications in critical care units. [Extracted from the article]

A study conducted by Mashhad University of Medical Sciences in Iran examined the effectiveness of a training package on the prevention of ventilator-associated pneumonia (VAP) using a blended online learning (BOL) method. The study involved 60 nurses from intensive care units (ICUs) in two hospitals. The nurses in the BOL group received a 45-minute online training session followed by virtual videos and group discussions, while the control group received two 2-hour online training sessions. The results showed that the BOL method was effective in improving the knowledge and performance of nurses in preventing VAP. This study suggests that the BOL method can be a suitable training method for VAP prevention programs. [Extracted from the article]

A recent study conducted at Jackson Memorial Hospital compared the outcomes of patients receiving shorter (8 days) versus longer (>8 days) antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia. The study found that prolonging treatment duration beyond 8 days did not improve patient outcomes for this type of pneumonia. The research suggests that the current guideline of at least 7 days of treatment may be sufficient for hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [Extracted from the article]

A study conducted in Delhi, India, examined the impact of compliance with a ventilator bundle care protocol on the rates of ventilator-associated pneumonia (VAP) in a neonatal intensive care unit (NICU). The study enrolled 95 neonates in the NICU and implemented a standardized VAP bundle care protocol. Compliance with the bundle care increased in the post-bundle study group, resulting in a decrease in VAP rates from 37.6 to 25.5 per 1000 mechanical ventilation days. The study concluded that increased compliance with ventilator bundle care can lead to a decrease in VAP rates, shorter hospital stays, and reduced antibiotic use in neonatal care. [Extracted from the article]

A recent study conducted by researchers at the University of Maryland School of Medicine explores the issue of overtreatment of ventilator-associated pneumonia (VAP) in intensive care units (ICUs). The study suggests that antibiotic treatment for VAP is often driven by positive respiratory tract cultures, even in the absence of clinical symptoms of pneumonia. The researchers propose the use of diagnostic stewardship, specifically modifying the reporting of lower respiratory tract (LRT) cultures, to improve antibiotic use for VAP. The study found that when LRT cultures were inappropriate, modifying the report to indicate potential colonization instead of organism identification led to a decrease in antibiotic therapy for VAP. The researchers conclude that diagnostic stewardship guided by clinical features of pneumonia could be an effective strategy for improving antibiotic use in VAP cases. [Extracted from the article]

A recent study conducted at Bharti Vidyapeeth Deemed University Medical College in Maharashtra, India, focused on ventilator-associated pneumonia (VAP), which is a common and serious infection acquired in hospitals. The study aimed to identify the bacteria responsible for VAP and their susceptibility to antibiotics. The researchers found that the majority of isolates were Gram-negative bacilli, with Klebsiella pneumoniae being the most common organism. The study emphasized the importance of judicious and appropriate use of antimicrobials to prevent the emergence of multidrug-resistant organisms and reduce mortality in VAP cases. [Extracted from the article]

A patent has been issued to Duke University for gene expression signatures that can be used to predict or diagnose sepsis. The inventors have identified specific gene expression patterns that are associated with sepsis and can be used to determine the risk of mortality in patients. The patent also includes methods for treating sepsis based on the determination of whether a patient has sepsis or is at risk of developing it. This research has the potential to improve the diagnosis and treatment of sepsis, a serious and potentially life-threatening condition. [Extracted from the article]

The article focuses on the effects of appropriate empirical antimicrobial treatment on patients with ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia. Topics include the impact of such treatment on mortality rates, the influence of previous antibiotic use, and the overall improvement in patient outcomes, including reduced hospital stay and ventilation duration.

The article focuses on new findings from University Health Network regarding hospital-acquired and ventilator-associated pneumonia in the early days following lung transplantation. Topics include the incidence and timing of pneumonia post-transplant, the genetic analysis of respiratory pathogens, and the association of pre-transplant conditions with increased risk and healthcare use.

The article focuses on research from Aristotle University of Thessaloniki examining the potential of blood lipid profiles for diagnosing ventilator-associated pneumonia (VAP) in critically ill pediatric patients. Topics include the use of untargeted lipidomics analysis to identify lipid species associated with VAP, the differentiation of blood lipid profiles between high and low VAP suspicion groups, and the correlation of specific lipids with microbial causes of VAP.

The article focuses on research from Xuzhou Medical University revealing that prior exposure to carbapenem antibiotics increases the risk of ventilator-associated pneumonia (VAP) in critically ill children. Topics include the impact of early antibiotic use on VAP incidence, the association between carbapenem exposure and VAP outcomes, and the identification of independent risk factors for VAP, such as carbapenem use and repeated intubation.

This document provides information about a research study being conducted in Egyptian pediatric intensive care units (PICUs) to investigate the incidence and risk factors of extubation failure (EF). Previous research has shown that EF is common in mechanically-ventilated patients and is associated with high mortality rates. The study aims to identify the causes of EF in the PICU and develop a local protocol for weaning patients off mechanical ventilation to reduce the risk of EF. The study is currently recruiting participants and is expected to be completed by May 2025. [Extracted from the article]

The article reports on a new clinical trial investigating the use of multiplex PCR in diagnosing ventilator-associated pneumonia (VAP) in the ICU. Topics discussed include the comparison of multiplex PCR to traditional bacterial culture methods, the potential impact on antibiotic stewardship, and the trial's aims to demonstrate clinical benefits in VAP management.

The article discusses a study from Zagazig University in Egypt that explores the microbial causes and biomarkers associated with ventilator-associated pneumonia (VAP). It mentions that the research identifies Klebsiella pneumoniae and Pseudomonas aeruginosa as prevalent pathogens and highlights the usefulness of biomarkers like C-reactive protein (CRP) and severity scores (SOFA and APACHE II) in predicting patient outcomes and survival.

The article focuses on a study comparing ventilator circuits to delay ventilator-associated pneumonia (VAP) in neurological patients. Topics include the effectiveness of conventional versus closed-loop ventilatory circuits, the timing of VAP onset, and the impact on patient outcomes such as duration of mechanical ventilation and hospital stay.

The article focuses on a systematic review from Al-Balqa' Applied University analyzing oral care and positioning methods for preventing ventilator-associated pneumonia (VAP). Topics include the effectiveness of oral care and positioning at a 45-degree angle in reducing VAP incidence, the methodological quality of included studies, and the need for further research on alternatives to oral chlorhexidine.

A researcher at the Medical University of Bialystok in Poland has conducted a systematic review on ventilator-associated tracheobronchitis (VAT), a lower respiratory tract inflammation that poses a significant challenge for intensive care units (ICUs) caring for mechanically ventilated patients. The study aims to provide a better understanding of VAT, which is considered an independent disease entity separate from ventilator-associated pneumonia (VAP). The review analyzes 31 articles published between 2004 and 2023 to systematize information on VAT, its diagnosis, treatment, and co-occurrence with other respiratory diseases. The research hopes to offer a fresh perspective on VAT and encourage further investigation in this area. [Extracted from the article]

A recent study conducted by researchers at the University of Sassari in Italy examined the efficacy and safety of ceftazidime-avibactam (CZA) alone versus CZA plus fosfomycin (FOS) for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The study included 75 episodes of nosocomial pneumonia, with 34 patients receiving CZA alone and 41 receiving CZA plus FOS. The study found no significant difference in survival at 28 days between the two treatment groups, but prolonged infusion was associated with a lower mortality rate. The researchers concluded that further investigations with larger samples are needed to evaluate the role of combination therapy in this setting. [Extracted from the article]

A patent has been issued to Stryker Corporation for a caregiver assistance system. The system is designed to assist caregivers in managing patient support apparatuses and performing various tasks such as administering medications, taking vital signs, and ensuring patient compliance. The system includes a tool that displays status data regarding the bed, notifications, and reminders for caregiver duties. It also provides alerts for unperformed tasks and records response times of caregivers. The system aims to improve patient care and reduce the risk of falls and bed sores. [Extracted from the article]

A clinical trial, NCT06517277, has been initiated to investigate Haemophilus influenzae pneumonia in adults. The Necker-Enfants Malades hospital has noticed a rise in respiratory infections caused by H. influenzae, with a high rate of relapses and recurrences despite appropriate treatment. The study will focus on lower respiratory infections in adults caused by H. influenzae in 13 hospitals in France over a 12-month period. The goal is to identify factors associated with relapse in hospitalized adult patients with Haemophilus influenzae pneumonia. The study is an observational one, collecting data from medical records, and is expected to be completed in February 2025. [Extracted from the article]

A new study conducted at Edouard Herriot Hospital has found that Pseudomonas aeruginosa, a drug-resistant bacteria, is a leading cause of healthcare-associated infections in Europe, resulting in increased patient morbidity and mortality. The study focused on a severely burned patient who experienced relapsing ventilator-associated pneumonia caused by extensively drug-resistant P. aeruginosa. The patient was successfully treated with personalized nebulized and intravenous phage therapy, along with immunostimulation and last-resort antimicrobial therapy. This research highlights the potential of phage therapy as an emerging option for treating severe P. aeruginosa infections. [Extracted from the article]

A new report from the University of Michigan provides insights into ventilator-associated pneumonia (VAP), a condition associated with increased mortality and longer hospital stays. The study found significant variation in the rate of VAP among trauma centers, with some hospitals identified as high or low outliers. The researchers suggest that investigating practices and factors influencing these differences could lead to improved outcomes. The study was funded by various organizations, including Blue Cross Blue Shield of Michigan and the Agency for Healthcare Research & Quality. [Extracted from the article]

A new report discusses research findings on ventilator-associated pneumonia (VAP) in non-cardiac surgical patients. The study, conducted at Kaohsiung Chang Gung Memorial Hospital in Taiwan, identified risk factors for VAP and determined the causative pathogens. The study found that VAP patients had a high mortality rate, and risk factors for mortality included late-onset VAP, inappropriate antibiotic treatment, and undergoing gastrointestinal surgeries. The research emphasizes the importance of identifying high-risk patients and understanding the resistant and microbial nature of VAP for improved treatment and health outcomes. [Extracted from the article]

A new report from Ain Shams University discusses the impact of residual gastric volume on the risk of ventilator-associated pneumonia (VAP) in adults receiving mechanical ventilation and early enteral feeding. The study found that monitoring residual gastric volume may lead to interruptions in nutrition delivery and inadequate feeding, without providing additional protection against VAP. The researchers recommend removing residual gastric volume monitoring from the standard care of critically ill patients receiving mechanical ventilation and early enteral nutrition. The study was conducted on critically ill patients admitted to ICU with mechanical ventilation and involved a sample size of 430 patients. [Extracted from the article]

A patent application has been filed for an intubation system that aims to reduce the risk of ventilator-associated pneumonia (VAP) in critically ill patients. VAP is a common nosocomial infection that affects intubated patients receiving mechanical ventilation. The system includes a base, a guide, and a connector for inserting an endotracheal tube into the patient. The system also features mechanisms for indicating the depth of insertion and inhibiting excessive insertion. The inventors propose that their system can simplify the process of intubation and reduce the risk of complications associated with VAP. [Extracted from the article]

A new study conducted by researchers at the University of Miami Miller School of Medicine has found that volatile organic compounds (VOCs) in heat and moisture exchange (HME) filters can potentially predict the presence of ventilator-associated pneumonia (VAP) in mechanically ventilated ICU patients. The researchers used gas chromatography-mass spectrometry (GC-MS) to analyze HME filters from 12 intubated patients who developed VAP. They found that carbon disulfide, which is associated with the proliferation of certain Gram-negative bacteria, was present in samples collected during pneumonia days for 11 out of 12 patients. This suggests that VOC sensors may be a useful adjunctive method for early detection of VAP. [Extracted from the article]

A new report discusses research conducted in Jiangxi, People's Republic of China, on the effectiveness of herbal oral care products in preventing ventilator-associated pneumonia (VAP) in mechanically ventilated patients. The study compared the effectiveness of herbal oral care products to Chlorhexidine (CHX), a traditional oral care solution. The results showed that Chinese herb and Miswak were more effective in reducing VAP incidence than CHX. However, further research is needed to validate the safety and feasibility of traditional Chinese herbal medicine. Matrica was found to reduce microbial counts but did not significantly lower the incidence of VAP. The study provides guidance for future research in this area. [Extracted from the article]

A recent study conducted by researchers at the University of Southern California Keck School of Medicine examined the incidence, risk factors, short-term outcomes, and microbiome of ventilator-associated pneumonia (VAP) in very-low-birth-weight (VLBW) infants born at less than 32 weeks of gestational age. The study found that VAP is a common hospital-acquired infection in neonates on invasive mechanical ventilation, with high morbidity and mortality rates. The most common causative organisms were Gram-positive organisms, particularly coagulase-negative Staphylococcus. Prolonged dexamethasone use was identified as a risk factor for VAP. The study highlights the need for preventive measures to reduce the incidence of VAP in this vulnerable population. [Extracted from the article]

A recent study conducted at the China-Japan Friendship Hospital in Beijing, China, focused on the prevention of hospital-acquired infections in organ transplant patients in the department of critical care medicine. The study highlighted the increased risk of infection in transplant patients due to immune suppression and emphasized the need for stricter management measures to prevent ventilator-associated pneumonia, catheter-related bloodstream infections, catheter-related urinary tract infections, and surgical site infections. The research aimed to provide guidance for clinical practice in critical care medicine. For more information, readers can refer to the journal article published in Xiehe Yixue Zazhi. [Extracted from the article]

A meta-analysis conducted by researchers at Anhui Chest Hospital in Hefei, China, examined the impact of bronchoscopy on patients with ventilator-associated pneumonia (VAP). The study included eight randomized controlled trials and three cohort studies, involving a total of 3,907 patients with suspected or diagnosed VAP. The findings showed that bronchoscopy use for the microbiological diagnosis of VAP did not reduce short-term mortality compared to diagnosis without bronchoscopy. However, therapeutic bronchoscopy use was associated with reduced mortality in these patients. The duration of mechanical ventilation and length of stay in the intensive care unit were not significantly different between groups. [Extracted from the article]